Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
06 März 2024 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, will publish its 2023
financial results on March 14, 2024, at 7.30am CET.
Sensorion’s management team will host a webcast on March 14,
2024, at 6pm CET to present the Company’s financial results and
provide an update on the Company’s activity.
The conference will be held in French and will be hosted by:
- Nawal Ouzren, Chief Executive Officer of
Sensorion - Géraldine Honnet, MD, Medical Director of Sensorion -
Laurent Désiré, PhD, Head of Preclinical Development at
Sensorion
Registration for the video conference can be accessed by
clicking on this link.
Participants will be able to submit questions live via the Teams
Conversation tool during the event.
Questions can also be submitted in advance to
sensorion@ulysse-communication.com.
A replay of the webinar will be available on Sensorion’s
website.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of novel therapies to restore, treat
and prevent hearing loss disorders, a significant global unmet
medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates. It has two gene
therapy programs aimed at correcting hereditary monogenic forms of
deafness, developed in the framework of its broad strategic
collaboration focused on the genetics of hearing with the Institut
Pasteur. SENS-501 (OTOF-GT) targets deafness caused by mutations of
the gene encoding for otoferlin and is currently developed in a
Phase 1/2 clinical study, and GJB2-GT targets hearing loss related
to mutations in GJB2 gene to potentially address important hearing
loss segments in adults and children. The Company is also working
on the identification of biomarkers to improve diagnosis of these
underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders. Sensorion’s clinical-stage portfolio includes one Phase
2 product: SENS-401 (Arazasetron) progressing in two Phase 2 proof
of concept clinical studies evaluating its efficacy to prevent
Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear
Limited, to prevent residual hearing loss in patients scheduled for
cochlear implantation. A Phase 2 study of SENS-401 was also
completed in Sudden Sensorineural Hearing Loss (SSNHL) in January
2022. www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2022 full year financial report published on March 30, 2023, and
available on our website and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305639678/en/
Investor Relations Noemie Djokovic, Investor Relations
and Communications Associate ir.contact@sensorion-pharma.com
International Media Relations Ulysse Communication
Pierre-Louis Germain / 00 33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
Bruno Arabian / 00 33 (0)6 87 88 47 26
barabian@ulysse-communication.com
Nicolas Entz / 00 33 (06) 33 67 31 54
nentz@ulysse-communication.com
Sensorion (EU:ALSEN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Sensorion (EU:ALSEN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024